Letaplimab

• Description :

  Letaplimab (IBI-188) is a human IgG4 anti-CD47 monoclonal antibody. CD47 is overexpressed on cancer cells, it is a ligand for SIRPα. Letaplimab enhances tumor cell phagocytosis[1].

• Product Name Alternative :

  IBI-188

• UNSPSC :

  12352203

• Target :

  Others

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Others

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/letaplimab.html

• Purity :

  95.00

• Solubility :

  10 mM in DMSO

• Smiles :

  [Letaplimab]

• Molecular Weight :

  (142.38 kDa)

• References & Citations :

  [1]Miao Miao, et al. A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome. MYELODYSPLASTIC SYNDROMES-CLINICAL AND EPIDEMIOLOGICAL NOVEMBER 15, 2022.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 2

• CAS Number :

  [2283356-07-8]